Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 20, 2024
Product Development

Triple-negative breast cancer attracts target innovation at AACR 

BioCentury identifies 44 new targets presented at meeting
BioCentury | Feb 10, 2023
Discovery & Translation

Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more

BioCentury's roundup of translational news
BioCentury | May 15, 2019
Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

BioCentury | Apr 13, 2017
Distillery Therapeutics

Cancer

BioCentury | Mar 30, 2017
Financial News

Promentis raises $26M in series C

BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Cancer

BioCentury | Sep 22, 2011
Distillery Therapeutics

Indication: Neurology

Items per page:
1 - 10 of 10